The 10th International Conference on COPD and Lung Health, taking place on June 15–16, 2026, at 09:30 AM in Paris, France. This landmark conference brings together pulmonologists, respiratory physicians, researchers, nurses, public health experts, and industry leaders from around the world to address the growing global burden of chronic obstructive pulmonary disease (COPD) and other lung disorders. Under the theme “Strengthening Global Strategies for Lung Health and COPD Control,” the conference will highlight the latest advances in prevention, early diagnosis, clinical management, digital respiratory care, and policy-driven approaches to improve respiratory outcomes. Through keynote lectures, scientific sessions, panel discussions, and networking opportunities, the meeting aims to foster collaboration, share evidence-based practices, and promote innovative, patient-centered solutions that strengthen lung health and reduce the impact of COPD worldwide.

Why to Attend?

Participating in the 10th International Conference on COPD and Lung Health offers a valuable opportunity for professionals in pulmonology, respiratory care, and public health to:

1. Gain insights into the latest research, clinical guidelines, and innovations in COPD and respiratory care
2. Learn from leading pulmonologists, researchers, and healthcare professionals through keynote talks and expert sessions
3. Explore global strategies for lung health promotion and COPD prevention and control
4. Understand emerging diagnostic tools, treatment modalities, and personalized care approaches
5. Discuss challenges in early diagnosis, disease management, and patient adherence
6. Discover advances in pulmonary rehabilitation, digital health, and tele-respiratory care
7. Network with international experts, clinicians, and industry leaders
8. Share research findings and clinical experiences in oral and poster sessions
9. Enhance professional knowledge and clinical skills for improved patient outcomes

Target Audience

The COPD and Lung Health Conference welcomes a diverse community of professionals, researchers, clinicians, and healthcare leaders involved in respiratory medicine and lung health, including:

1. Pulmonologists & Respiratory Physicians
2. Thoracic Surgeons
3. Internal Medicine Specialists
4. Critical Care & Emergency Physicians
5. Respiratory Therapists & Pulmonary Rehabilitation Specialists
6. Nurses & Nurse Practitioners in Respiratory Care
7. Clinical Researchers & Academicians
8. Public Health Professionals & Epidemiologists
9. Primary Care Physicians
10. Pharmacologists & Drug Development Experts
11. Biomedical Scientists & Translational Researchers
12. Healthcare Policy Makers & Regulators
13. Medical Device & Inhalation Technology Experts
14. Digital Health & Tele-respiratory Care Professionals
15. Graduate Students, Postdoctoral Fellows & Trainees

Scientific Sessions and Tracks

Track 1: Respiratory Infections & Comorbidities

This track focuses on the prevention, diagnosis, and management of respiratory infections and their impact on chronic lung diseases such as COPD and asthma. It highlights common infections, exacerbation triggers, antimicrobial resistance, and vaccination strategies, along with the role of comorbid conditions like cardiovascular disease, diabetes, and osteoporosis in disease progression. The session emphasizes integrated care approaches, early intervention, and multidisciplinary management to reduce complications and hospitalizations and improve overall respiratory health outcomes.

COPD comorbidities | Respiratory infections | Chronic bronchitis | Pneumonia | Tuberculosis | Viral respiratory infections | Bacterial infections | Exacerbations of COPD | Asthma–COPD overlap | Lung infections | Immune dysfunction | Antibiotic resistance | Inflammation

Track 2: COPD & Cardio-Metabolic Health

This track focuses on the complex interplay between COPD and common cardiovascular and metabolic conditions such as hypertension, coronary artery disease, diabetes, and metabolic syndrome. It explores shared risk factors, underlying inflammatory mechanisms, and the impact of comorbidities on disease progression, treatment outcomes, and mortality. Sessions will highlight integrated care approaches, multidisciplinary management strategies, and evidence-based interventions to improve overall patient outcomes and quality of life.

COPD | Cardiovascular disease | Metabolic disorders | Hypertension | Diabetes mellitus | Systemic inflammation | Comorbidity management | Integrated care | Multidisciplinary approach | Patient outcomes

Track 3: Allied Health in Respiratory Care

This track highlights the essential role of allied health professionals in the comprehensive management of respiratory diseases, including COPD and other chronic lung conditions. It focuses on respiratory therapy, pulmonary rehabilitation, physiotherapy, occupational therapy, nutrition support, and patient education aimed at improving breathing function, exercise tolerance, and quality of life. Emphasis is placed on multidisciplinary teamwork, evidence-based interventions, home-based care, and long-term disease self-management to enhance patient outcomes across clinical and community settings.

Respiratory therapy | Pulmonary rehabilitation | Physiotherapy | Occupational therapy | Multidisciplinary care | Patient education | Breathing techniques | Home-based care | Chronic lung disease management | Quality of life

Track 4: Quality of Life in Lung Health

This track focuses on improving the physical, emotional, and social well-being of individuals living with chronic lung diseases. It highlights symptom control, patient education, self-management strategies, pulmonary rehabilitation, and psychosocial support aimed at enhancing daily functioning and long-term quality of life.

Quality of life | Patient-reported outcomes | Symptom management | Pulmonary rehabilitation | Self-management | Patient education | Psychosocial support | Chronic lung disease | COPD care | Patient-centered care

Track 5: Advances in COPD Pharmacotherapy

This track highlights the latest developments in pharmacological treatments for COPD, focusing on novel bronchodilators, combination inhaler therapies, anti-inflammatory agents, and biologics. It covers personalized treatment strategies, optimizing drug delivery, managing exacerbations, and improving symptom control and long-term outcomes through evidence-based medication approaches.

COPD pharmacotherapy | Bronchodilators | Inhaled corticosteroids | Triple therapy | Biologic drugs | Personalized medicine | Drug delivery systems | Exacerbation management | Precision treatment | Clinical guidelines

Track 6: AI-Driven Respiratory Care

This track explores how artificial intelligence and digital technologies are transforming respiratory care and pulmonology. It highlights AI-based diagnostic tools, predictive analytics for disease progression and exacerbations, smart spirometry, imaging analysis, and remote patient monitoring for conditions such as COPD and asthma. The session also covers clinical decision support systems, tele-pulmonology, personalized treatment planning, and the integration of AI into routine respiratory practice to improve accuracy, efficiency, and patient outcomes.

Artificial Intelligence | Digital Pulmonology | Predictive Analytics | Smart Spirometry | AI Imaging | Remote Patient Monitoring | Tele-Pulmonology | Clinical Decision Support | Personalized Respiratory Care | COPD Management

Track 7: Next-Gen COPD Treatments

This track explores emerging and future-focused therapeutic strategies transforming the management of chronic obstructive pulmonary disease (COPD). It highlights novel pharmacological agents, precision inhaler technologies, biologics, and anti-inflammatory therapies aimed at improving symptom control and slowing disease progression. Sessions will also cover advances in regenerative medicine, stem cell research, gene-based approaches, and targeted molecular therapies. Ongoing and upcoming clinical trials, real-world evidence, and personalized treatment strategies based on disease phenotypes and biomarkers will be discussed. The track emphasizes innovation, translational research, and the path from clinical trials to routine COPD care.

Next-generation COPD therapies | Novel bronchodilators | Biologic treatments | Precision medicine | Targeted therapy | Regenerative medicine | Stem cell therapy | Gene therapy | Anti-inflammatory agents | Personalized COPD treatment | Biomarkers

Track 8: Personalized Respiratory Medicine

This track focuses on precision and personalized approaches to respiratory care, particularly in COPD and chronic lung diseases. It highlights the use of biomarkers, genetic profiling, phenotyping, and patient-specific data to tailor prevention, diagnosis, and treatment strategies. Sessions will explore targeted therapies, predictive analytics, and individualized care plans that improve treatment effectiveness, reduce adverse effects, and enhance long-term outcomes in diverse patient populations.

Precision medicine | Personalized care | Biomarkers | COPD phenotypes | Genomics | Targeted therapies | Predictive modeling | Individualized treatment | Patient stratification | Outcome optimization

Track 9: COPD Pathophysiology

This track focuses on the underlying biological and physiological mechanisms of Chronic Obstructive Pulmonary Disease (COPD). It explores airway inflammation, oxidative stress, structural lung changes, mucus hypersecretion, and alveolar destruction that contribute to airflow limitation and disease progression. Sessions will also address genetic susceptibility, environmental risk factors such as smoking and air pollution, and the role of immune dysregulation. Understanding COPD pathophysiology is emphasized as a foundation for early diagnosis, targeted therapies, and the development of personalized treatment strategies.

COPD mechanisms | Airway inflammation | Chronic airflow limitation | Oxidative stress | Lung remodeling | Alveolar destruction | Emphysema | Chronic bronchitis | Protease–antiprotease imbalance | Immune dysregulation | Genetic susceptibility | Environmental risk factors | Smoking-related lung damage | Air pollution exposure

Track 10: Virtual Respiratory Care

This track explores the use of telemedicine and remote monitoring technologies in respiratory care to improve access, continuity, and outcomes for patients with COPD and other lung diseases. It highlights virtual consultations, home-based monitoring, wearable devices, digital spirometry, and tele-rehabilitation programs that support early detection of exacerbations, treatment adherence, and patient self-management—especially for elderly, rural, and high-risk populations.

Tele-pulmonology | Remote patient monitoring | Virtual consultations | Digital spirometry | Wearable respiratory devices | Tele-rehabilitation | Home-based COPD care | mHealth apps | Chronic disease monitoring | Virtual care models

Track 11: Novel COPD Treatments

This track explores emerging and innovative treatment approaches transforming COPD management. It highlights novel pharmacological agents, biologics, regenerative therapies, and anti-inflammatory strategies aimed at slowing disease progression and improving lung function. Sessions will also cover advances in inhaler technologies, combination therapies, and personalized treatment strategies, along with insights from ongoing and upcoming clinical trials shaping the future of COPD care.

Novel therapies | COPD drug development | Biologics in COPD | Regenerative medicine | Anti-inflammatory agents | Targeted therapies | New inhaler technologies | Combination treatments | Clinical trials | Future COPD management

Track 12: Pediatric Respiratory Care

This track focuses on the prevention, diagnosis, and management of respiratory conditions in infants, children, and adolescents. It covers common and chronic pediatric lung disorders such as asthma, bronchitis, pneumonia, cystic fibrosis, and early-life wheezing disorders. Emphasis is placed on early detection, age-appropriate treatment strategies, vaccination, environmental risk reduction, and long-term monitoring to improve respiratory outcomes into adulthood. The track also highlights the role of pediatric nurses, family-centered care, and public health interventions in promoting lifelong lung health.

Pediatric lung health | Childhood respiratory diseases | Pediatric asthma | Early-life respiratory disorders | Pediatric pneumonia | Cystic fibrosis | Neonatal lung care | Vaccination & prevention | Environmental exposure

Track 13: COPD Immune Responses

This track explores the role of immune and inflammatory mechanisms in the development, progression, and exacerbation of COPD. It focuses on chronic airway inflammation, immune cell dysfunction, cytokine signaling, oxidative stress, and host–pathogen interactions that contribute to lung tissue damage. Sessions will highlight emerging immunomodulatory therapies, biomarkers of inflammation, and personalized approaches targeting immune pathways to improve disease control and patient outcomes.

COPD inflammation | immune dysregulation | cytokines | innate immunity | adaptive immunity | oxidative stress | airway inflammation | immune biomarkers | immunotherapy | exacerbation pathways

Track 14: Ventilatory Support in Lung Care

This track focuses on the essential role of ventilatory support in the management of acute and chronic lung diseases, including COPD, respiratory failure, and critical care conditions. It covers non-invasive and invasive ventilation strategies, oxygen delivery systems, mechanical ventilation protocols, and weaning approaches. Emphasis is placed on optimizing ventilation settings, improving patient comfort, preventing ventilator-associated complications, and enhancing outcomes across hospital, home-care, and emergency settings. The session also highlights advances in ventilatory technologies and the role of multidisciplinary teams in delivering effective respiratory support.

Ventilatory Support | Mechanical Ventilation | Non-Invasive Ventilation (NIV) | Invasive Ventilation | Oxygen Therapy | Respiratory Failure | COPD Management | Ventilator Weaning | Critical Care Pulmonology | Home Ventilation

Track 15: Fibrosis & Chronic Lung Care

This track focuses on the diagnosis, management, and long-term care of pulmonary fibrosis and other chronic lung disorders. It highlights disease mechanisms, early detection strategies, and advances in pharmacological and supportive therapies aimed at slowing disease progression and improving patient outcomes. Sessions will also address symptom management, pulmonary rehabilitation, oxygen therapy, and palliative approaches, with emphasis on multidisciplinary care and enhancing quality of life for patients living with chronic lung diseases.

Pulmonary fibrosis | Chronic lung disease | Interstitial lung disease | Lung scarring | Disease progression | Antifibrotic therapy | Pulmonary rehabilitation | Oxygen therapy | Breathlessness management | Multidisciplinary care | Quality of life | Long-term lung care

Track 16: Asthma–COPD Overlap

This track focuses on the diagnosis and management of Asthma–COPD Overlap, a condition characterized by features of both asthma and chronic obstructive pulmonary disease. It highlights challenges in accurate diagnosis, overlapping inflammatory pathways, and disease phenotyping. Sessions will discuss personalized treatment strategies, including inhaled therapies, biologics, and non-pharmacological interventions. Emphasis is placed on improving symptom control, reducing exacerbations, and enhancing long-term outcomes through integrated and patient-centered care.

Asthma–COPD Overlap | ACO | Airway Inflammation | Disease Phenotyping | Differential Diagnosis | Personalized Therapy | Inhaled Corticosteroids | Bronchodilators | Biologics | Exacerbation Management | Precision Respiratory Medicine

Track 17: Lung Rehabilitation & Lifestyle Care

This track focuses on comprehensive, patient-centered approaches to improving respiratory health and quality of life in individuals with chronic lung diseases. It highlights the role of pulmonary rehabilitation programs that combine supervised exercise training, breathing techniques, education, and psychosocial support to enhance functional capacity and reduce symptom burden. Emphasis is placed on lifestyle modifications such as smoking cessation, nutrition optimization, physical activity, stress management, and adherence to treatment plans. The track also explores community-based rehabilitation, home-based care models, and the integration of multidisciplinary teams to support long-term lung health and prevent disease progression.

Pulmonary rehabilitation | Lung rehabilitation | Chronic lung disease management | Exercise training | Breathing techniques | Respiratory physiotherapy | Lifestyle modification | Smoking cessation | Physical activity | Nutrition and lung health | Patient education

Track 18: COPD Drug Therapy

This track focuses on current and emerging pharmacological approaches for the management of Chronic Obstructive Pulmonary Disease (COPD). It covers the appropriate use of bronchodilators, inhaled corticosteroids, combination therapies, and personalized treatment strategies based on disease severity and patient phenotypes. Discussions also include the management of acute exacerbations, prevention of disease progression, medication adherence, inhaler techniques, and the development of novel drugs targeting inflammation, mucus hypersecretion, and airway remodeling. Emphasis is placed on evidence-based guidelines and optimizing therapy to improve lung function, reduce exacerbations, and enhance patient quality of life.

COPD pharmacotherapy | Bronchodilators | Inhaled corticosteroids | Long-acting beta agonists (LABA) | Long-acting muscarinic antagonists (LAMA) | Combination inhaler therapy | Acute exacerbation management | Personalized treatment

Participation Options

COPD and Lung Health 2026 offers participation opportunities across Academic, Student, and Industry categories.

1. Keynote Speaker: 45-50 minutes
2. Oral Presentation: 25-30 minutes (individual presenters only)
3. Workshop: 45-50 minutes (multiple presenters allowed)
4. Special Session: 45-50 minutes (multiple presenters allowed)
5. Symposium: Over 45 minutes (multiple presenters allowed)
6. Delegate Registration: Access to all sessions with full benefits
7. Poster Presenter: Opportunity to present a poster and access delegate benefits
8. Remote Attendance: Participate via virtual mode, video presentation, or e-poster
9. Exhibitor: Showcase products through various booth sizes
10. Media Partner, Sponsor, Collaborator

Benefits of participation

Benefits for Speakers

1. All accepted abstracts will be published in relevant journals.
2. Attendees receive CPD credits and official participation certificates.
3. Gain global visibility for your research in COPD and lung health.
4. Access valuable opportunities for professional growth and skill development.
5. Stay updated with the latest advances in respiratory and pulmonary research.
6. Build lasting professional connections through dedicated networking sessions.
7. Promote your work through abstract books and conference materials with wide global reach.
8. Explore interdisciplinary topics beyond your core focus in respiratory medicine.

Benefits for Delegates

1. Broaden your knowledge and advance your professional expertise in COPD and lung health care.
2. Reignite your passion and motivation through engaging scientific sessions, case discussions, and expert panels.
3. Explore and support innovative approaches aimed at improving respiratory outcomes and quality of life for patients with chronic lung diseases.
4. Connect and network with leading researchers, pulmonologists, respiratory therapists, and healthcare professionals in COPD management, pulmonary rehabilitation, and lung medicine.
5. Gain practical insights into early diagnosis, personalized therapies, and long-term disease management strategies.
6. Engage with emerging technologies and digital innovations transforming respiratory care and monitoring.

Benefits for Sponsors

1. Enhance brand visibility and recognition in the global COPD and lung health marketplace.
   Showcase your latest respiratory products, technologies, devices, and services to a targeted international audience.
2. Generate high-quality leads and unlock new business growth opportunities in pulmonary care.
3. Build strong relationships and strategic partnerships with industry leaders, clinicians, and decision-makers in respiratory health.
4. Participate in insightful discussions that help refine and strengthen commercial and clinical business strategies.
5. Benchmark your solutions against leading organizations to remain competitive and innovative in the lung health sector.
6. Gain practical solutions to organizational and market challenges through direct interaction with experts and key opinion leaders in pulmonology.

Benefits for Collaborators

1. Access a high-traffic platform for enhanced visibility at the COPD and Lung Health Conference.
2. Build lasting professional relationships with global respiratory health experts and stakeholders.
3. Expand your organization’s reach through marketing materials displayed throughout the conference.
4. Increase your association’s visibility within the international pulmonary and lung health community.
5. Engage directly with key delegates to share insights about your organization, products, and services.
6. Feature your branding in conference materials distributed to hospitals, universities, research institutions, and public health organizations worldwide.

Elite Sponsor Benefits

1. Opportunity to sponsor 10 Poster Presentation Awards at the COPD and Lung Health Conference.
2. Three corporate-sponsored workshop slots with full audio-visual support included.
3. Two complimentary exhibition booths (3×3 sqm) with priority location selection.
4. Four complimentary conference registrations for sponsor representatives.
5. Prominent logo visibility on the congress website homepage, sponsorship page, and associated journal platforms.
6. One full-page color advertisement in the congress program or abstract book (excluding cover pages).
7. Three promotional inserts supplied by the sponsor included in delegate bags.
8. One post-conference email campaign to registered attendees (within 60 days, sponsor content subject to approval).
9. Exclusive online promotion across official social media channels.
   Enjoy a 20% discount on sponsorship for any conference organized next year.

Gold Sponsor Benefits

1. Opportunity to sponsor 5 Poster Presentation Awards at the conference.
2. Two corporate-sponsored workshop slots, including catering and full audio-visual support (subject to deadline adherence).
3. One complimentary exhibition booth (3×3 sqm) with priority location selection.
4. Three complimentary congress registrations for sponsor representatives.
5. Prominent logo visibility on the congress website homepage and sponsorship page.
6. One full-page color advertisement in the congress program or abstract book (excluding cover pages).
7. Two promotional inserts supplied by the sponsor included in delegate bags.
8. Exclusive online promotion across official social media platforms.
9. Receive a 15% discount on sponsorship for any conference organized next year.

Silver Sponsor Benefits

1. Opportunity to sponsor 3 Poster Presentation Awards.
2. Two complimentary congress registrations for sponsor representatives.
3. One corporate-sponsored workshop slot, including catering and full audio-visual support (subject to deadline adherence).
4. One complimentary exhibition booth (3×3 sqm) with priority location selection.
5. Logo visibility on the congress sponsorship page of the official website.
6. One full-page color advertisement in the congress program or book of abstracts (excluding cover pages).
7. One promotional insert supplied by the sponsor included in delegate bags.
8. Priority access to purchase additional sponsorship opportunities.
9. Exclusive online promotion across all official social media platforms.
10. Enjoy a 10% discount on sponsorship for any conference organized next year.

Market Outlook

The COPD and Lung Health market in 2026 represents a strong and expanding global opportunity, driven by rising disease prevalence, aging populations, pollution exposure, and advances in treatment and care delivery. The global COPD market (including therapeutics and disease management) is estimated to reach USD 25–32 billion by 2026, growing at a CAGR of approximately 7–8%, supported by increasing adoption of combination inhalers, biologics, and personalized therapies. The broader respiratory disorders treatment market is projected to reach around USD 128 billion in 2026, with a CAGR of about 6%, reflecting sustained demand across asthma, COPD, and chronic lung conditions. In parallel, the respiratory and pulmonary care devices market (including ventilators, oxygen therapy, and monitoring devices) is expected to reach ~USD 28 billion in 2026, growing at a CAGR of 6–9%, fueled by home-based care, digital monitoring, and non-invasive ventilation technologies. Together, these trends highlight COPD and lung health as a high-growth, innovation-driven sector with significant clinical and commercial momentum heading into 2026.